Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib

We explored the impact of early molecular response (EMR; BCR-ABL ≤10% on the international scale [BCR-ABL(IS)] at 3 or 6 months) on outcomes in patients with newly diagnosed chronic myeloid leukemia in chronic phase treated with nilotinib or imatinib based on 4 years of follow up in Evaluating Nilot...

Full description

Saved in:
Bibliographic Details
Published in:Blood
Main Authors: Hughes, Timothy P., Saglio, Giuseppe, Kantarjian, Hagop M., Guilhot, François, Niederwieser, Dietger, Rosti, Gianantonio, Nakaseko, Chiaki, De Souza, Carmino Antonio, Kalaycio, Matt E., Meier, Stephan, Fan, Xiaolin, Menssen, Hans D., Larson, Richard A., Hochhaus, Andreas
Format: Artigo
Language:Inglês
Published: American Society of Hematology 2014
Subjects:
Myeloid Neoplasia
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC4624459/
https://ncbi.nlm.nih.gov/pubmed/24335106
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2013-06-510396
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items